Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- Bevacizumab for Recurrent Glioblastoma
NCT02337491Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2015
- Primary completion
- Aug 2016
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in glioblastoma (GBM), sponsored by Dana-Farber Cancer Institute. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02337491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337491.